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BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating concentrations of oestrogens and
androgens, but the determinants of these hormones are not well understood.
METHODS: Cross-sectional analyses of breast cancer risk factors and circulating hormone concentrations in more than 6000
postmenopausal women controls in 13 prospective studies.
RESULTS: Concentrations of all hormones were lower in older than younger women, with the largest difference for
dehydroepiandrosterone sulphate (DHEAS), whereas sex hormone-binding globulin (SHBG) was higher in the older women.
Androgens were lower in women with bilateral ovariectomy than in naturally postmenopausal women, with the largest difference for
free testosterone. All hormones were higher in obese than lean women, with the largest difference for free oestradiol, whereas
SHBG was lower in obese women. Smokers of 15þ cigarettes per day had higher levels of all hormones than non-smokers, with the
largest difference for testosterone. Drinkers of 20þ g alcohol per day had higher levels of all hormones, but lower SHBG, than
non-drinkers, with the largest difference for DHEAS. Hormone concentrations were not strongly related to age at menarche, parity,
age at first full-term pregnancy or family history of breast cancer.
CONCLUSION: Sex hormone concentrations were strongly associated with several established or suspected risk factors for breast
cancer, and may mediate the effects of these factors on breast cancer risk.
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Breast cancer risk for postmenopausal women is positively
associated with the circulating concentrations of oestrogens and
androgens (Endogenous Hormones and Breast Cancer Collabora-
tive Group, 2002; Missmer et al, 2004; Kaaks et al, 2005). The
increase in risk of postmenopausal breast cancer associated with
obesity may be largely explained by the relatively high circulating
concentrations of free oestradiol in obese postmenopausal women
(Endogenous Hormones and Breast Cancer Collaborative Group,
2003a; Rinaldi et al, 2006), but it is unclear to what extent the
effects of other risk factors may be mediated by their associations
with circulating sex hormones. A number of previous studies have
examined the associations of circulating sex hormones with known
and possible breast cancer risk factors, such as age at menarche,
parity, age at first full-term pregnancy, type of menopause,
smoking and alcohol, but they have not been large enough to
provide definitive results (see Discussion). The Endogenous
Hormones and Breast Cancer Collaborative Group was established
to conduct collaborative analyses of individual data from
prospective studies of endogenous hormones and breast cancer.
We report here the cross-sectional associations of circulating
concentrations of sex hormones and sex hormone-binding
globulin (SHBG) with 12 demographic, reproductive and lifestyle
factors.
MATERIALS AND METHODS
Data collection
Published studies were eligible for the collaborative reanalysis if
they included data on endogenous hormones and breast cancer
risk using prospectively collected blood samples from postmeno-
pausal women, as described previously (Endogenous Hormones
and Breast Cancer Collaborative Group, 2002). Studies were
identified by computer-aided literature searches, within relevant
review articles, and through our discussions with colleagues.
Studies were eligible for inclusion if they had published peer-
reviewed data on endogenous hormone concentrations and breast
cancer risk using prospectively collected blood samples from
postmenopausal women. The data reported here are for the
standardised database as available for analysis by the collaborative
group in late 2010. The studies included were: CLUE I, Washington
County, MD, USA (Wysowski et al, 1987; Gordon et al, 1990;
Helzlsouer et al, 1994); Columbia, MO, USA (Dorgan et al, 1996,
1997); European Prospective Investigation into Cancer and
Nutrition (EPIC), Europe (Kaaks et al, 2005); Guernsey, UK
(Thomas et al, 1997); Malmo¨/Umea˚, Sweden (Manjer et al, 2003);
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the Melbourne Collaborative Cohort Study (MCCS), Australia
(Baglietto et al, 2009); Nurses’ Health Study, USA (Hankinson et al,
1998); New York University Women’s Health Study (NYU WHS),
USA (Toniolo et al, 1995; Zeleniuch-Jacquotte et al, 1997, 2004);
Study of Hormones and Diet in the Etiology of Breast Tumors
(ORDET), Italy (Berrino et al, 1996); Rancho Bernardo, USA
(Barrett-Connor et al, 1990; Garland et al, 1992); Radiation Effects
Research Foundation (RERF), Japan (Kabuto et al, 2000); Study of
Osteoporotic Fractures (SOF), USA (Cauley et al, 1999); and the
Women’s Health Initiative, Observational Study (WHI-OS), USA
(Gunter et al, 2009). Details of the recruitment of participants,
informed consent and definitions of reproductive variables are in
the original publications. Height and weight were measured in
eight studies (EPIC (most centres), Guernsey, Malmo¨/Umea˚,
MCCS, ORDET, Rancho Bernardo, SOF and WHI-OS) and were
self-reported in four studies (Columbia, Nurses’ Health Study,
NYU WHS and RERF). With the exception of the RERF Study in
Japan, the majority of the women in these studies were of white
European ethnic origin.
Collaborators were asked to provide data on concentrations of
the hormones oestradiol (total), free oestradiol, oestrone, andros-
tenedione, dehydroepiandrosterone sulphate (DHEAS), testoste-
rone, free testosterone and SHBG, where available. Details of the
assays and median hormone concentrations for the data included
in our analyses are in Table 1. Data from CLUE I were analysed as
two substudies because of changes in the assay method for
oestradiol, oestrone and androstenedione between the first phase
and the second phase. Data for oestradiol from the Malmo¨/Umea˚
Study were not included because over 50% of recorded values were
below the detection limit of the assay. The majority of studies
measured hormone concentrations in serum, whereas some
(Malmo¨/Umea˚, MCCS, Nurses’ Health Study and Rancho Bernardo)
used plasma. Circulating concentrations of free oestradiol and free
testosterone were calculated from the concentrations of oestradiol
and testosterone, respectively, and SHBG, with albumin assumed
to be constant (40 g l1), according to the law of mass action
(Sodergard et al, 1982; Endogenous Hormones and Breast Cancer
Collaborative Group, 2003b); in the subset of studies that had
measured free oestradiol and free testosterone, the correlations of
these values with the calculated values were 0.98 and 0.77,
respectively, and using calculated values for all participants
increased the sample size for these analyses, while standardizing
the estimation approach.
Collaborators also provided data on reproductive and anthro-
pometric factors for each woman in their study. Women who were
using hormone replacement therapy or other exogenous sex
hormones at the time of blood collection were excluded. All studies
that contributed data to the analysis were cohorts in which blood
samples were collected from women who were then followed to
identify those subjects who developed breast cancer. The analyses
in this paper use data only from the ‘control’ women who had not
developed breast cancer during the follow-up period in each
contributing study.
Statistical analysis
Hormone and SHBG concentrations were logarithmically trans-
formed to normalise the distributions. A few hormone and SHBG
values recorded as zero were reset to a suitably small non-zero
value to allow logarithmic transformation: 1 pmol l1, 0.01, 0.01
and 1 nmol l1 for oestradiol (1 value), androstenedione (3 values),
testosterone (16 values) and SHBG (2 values), respectively.
Partial correlations between the hormones and SHBG were
computed using study-specific standardised values: (xjk-mj)/sj,
where mj and sj denote the mean and standard deviation of the log-
transformed hormone concentrations in study j and xjk is an
observation from that study. These standardised values were
adjusted for age at blood collection (continuous), type of
menopause (natural, hysterectomy, bilateral ovariectomy) and
body mass index (BMI; continuous) for women with known values
for these variables. The use of standardisation effectively adjusts
for the differences in mean hormone concentration between
studies.
Geometric mean hormone and SHBG concentrations by
categories of various factors, together with their 95% confidence
intervals, were calculated using the predicted values from analysis
of variance models scaled to the overall geometric mean
concentration. The factors examined were age (o55, 55 –59,
60–64, 65–69 and 70þ years), type of menopause (natural,
hysterectomy, bilateral ovariectomy, other or unknown), BMI
Table 1 Assay methods and median hormone and SHBG concentrations
Oestradiol Oestrone Androstenedione DHEAS Testosterone SHBG
Study,
country Method
CV,
%
Median
(dl),
pmol l1 Method
CV,
%
Median
(dl),
pmol l1 Method
CV,
%
Median
(dl),
nmol l1 Method
CV,
%
Median
(dl),
nmol l1 Method
CV,
%
Median
(dl),
nmol l1 Method
CV,
%
Median
(dl),
nmol l1
CLUE I, USA phase 1 CP RIA — 161.5 CP RIA — 183 CP RIA 5.48 CP RIA 0.81
CLUE I, USA phase 2 E RIA 7.1 58.7 E RIA 9.9 141 E RIA 10.0 2.74 NE RIA 2.4 1815 IA 10.9 55.8
Columbia, MO, USA NE RIA 23.7 51.4 NE RIA 5.0 129 NE RIA 1.3 3.11 NE RIA 0.7 2204 NE RIA 5.8 0.59 IRMA 1.6 53.4
EPIC, Europe NE RIA 5.8 89.1 NE RIA 10.2 145 NE RIA 4.8 3.04 NE RIA 7.0 2034 NE RIA 10.8 1.21 IRMA 8.0 34.5
Guernsey, UK E RIA 15.1 35.0 (3.0) NE RIA 9 2041 NE RIA 4.5 0.91 (0.35) IRMA 4.1 63.0
Malmo¨/Umea˚, Sweden NE RIA 20.6 74 (4.44) E RIA p15 2.33 (0.14) NE RIA p15 2730 (200) E RIA p15 1.22 (0.1) IMF p15 55.4
MCCS, Australia NE ECIA 10 57.0 (18) NE RIA 15 2.15 (0.02) NE CIA 10 1500 (200) NE ECIA 7 0.70 (0.1) IRMA 7 50.7(2)
Nurses’ Health Study,
USA
E RIA 11.0 22.0 (7.3) E RIA 12.1 89 (37.0) E RIA 12.1 1.99 (0.10) NE RIA 9.0 2313 (136) E RIA 12.3 0.76 (0.035) IA 15.5 47.7
NYU WHS, USA NE RIA 13.2 81.8 NE RIA 14.4 99 NE RIA 13.5 2.46 NE RIA 14.7 2144 NE RIA 15.8 0.79 IRMA 13.5 48.1
ORDET, Italy E RIA 9.6 21.7 NE RIA 3.7 2004 NE RIA 7.3 1.17 IRMA 4.4 41.5
Rancho Bernardo,
USA
E RIA 7.1 40.4 (11) E RIA 7.7 113 (11) E RIA 4.3 1.92 (0.06) NE RIA 10 1755 (52) E RIA 4.9 0.75 (0.07) Binding
assay
11.4 29.0
RERF, Japan NE RIA 9.8 65.2 NE RIA — 952 RIA 5.3 67.3
SOF, USA E RIA 11 22.0 (7.3) E RIA 17 74 (37.0) E RIA 16 1.29 (0.1) NE RIA 12 1742 (170) CP RIA 13 0.62 (0.03) RIA 7.8 42.3 (5)
WHI-OS, USA NE IA 5.9 40.4 (18.4)
Abbreviations: CIA¼ competitive immunoassay; CLUE¼Washington County, MD Study ‘Give us a clue to cancer and heart disease’; CP¼ chromatographic purification;
CV¼ coefficient of variation: total if reported, otherwise between assay, otherwise within assay; dl¼ detection limit; E¼ extraction step; ECIA¼ electrochemiluminescence
immunoassay; EPIC¼ European Prospective Investigation into Cancer and Nutrition; IA¼ immunoassay; IMF¼ immunofluorometry; IRMA¼ immunoradiometric assay;
MCCS¼Melbourne Collaborative Cohort Study; NE¼ no extraction step; NYU WHS¼New York University Women’s Health Study; ORDET¼ Study of Hormones and Diet
in the Etiology of Breast Tumors; RIA¼ radioimmunoassay; RERF¼Radiation Effects Research Foundation; SHBG¼ sex hormone-binding globulin; SOF¼ Study of Osteoporotic
Fractures; WHI-OS¼Women’s Health Initiative, Observational Study.
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(calculated as weight in kilograms divided by the square of height
in metres and categorised as o22.5, 22.5–24.9, 25.0–27.4,
27.5– 29.9 and 30.0þ kg m2), smoking (never, previous, current
o15 cigarettes day and current 15þ cigarettes per day), alcohol
(none, o10 g per day, 10–19 g per day and 20þ g per day (a 4 oz
glass of wine typically contains 12 g of alcohol)), age at menarche
(o12, 12– 13 and 14þ years), number of full-term pregnancies
(none, 1, 2, 3 and 4þ ), age at first full-term pregnancy (o25 and
25þ years), years since menopause (0– 4, 5–14 and 15þ years),
family history of breast cancer (no and yes), previous use of
hormonal contraceptives (no and yes) and previous use of
hormone therapy (no and yes).
The geometric mean hormone concentrations were adjusted for
study, age at blood collection, type of menopause and BMI, as
appropriate (categories as above, with an extra ‘unknown’ category
for BMI, which was unknown for 4% of women with values for
oestradiol). Heterogeneity between categories was assessed by
F tests arising from the analysis of variance. Trends in hormone
concentrations across categories of all quantitative variables except
alcohol were tested by scoring the categories from 1 to the
maximum number of categories and treating them as continuous
variables in the analysis of variance. Alcohol was treated differently
because of the highly skewed distribution of intakes, and the
alcohol consumption categories were scored 0, 3, 12 and 30,
respectively, in the tests for linear trend in accordance with the
median daily alcohol intake in grams in those categories. Values
for BMI, smoking, alcohol consumption and most of the other
factors investigated were unknown for some women, and these
individuals were excluded from the analyses of hormones in
relation to these factors. Tests of heterogeneity between studies in
the associations of hormones with other factors were obtained by
adding a study-by-factor interaction term to the analysis of
variance and using the F-test to assess its significance. For
oestradiol (and free oestradiol), oestrone, androstenedione and
testosterone (and free testosterone), the results were examined
according to whether or not the hormone assay had included a
purification step (usually by organic solvent extraction and
column chromatography). CLUE I; Nurses’ Health Study; Rancho
Bernardo; and SOF used purification steps in the assays for all of
these analytes, and Columbia, MO; EPIC; NYU WHS; RERF; and
WHI used all direct assays, whereas Guernsey and ORDET used
extraction for oestradiol and direct assays for testosterone, and
Malmo¨/Umea˚ used direct assays for oestrone and extraction for
androstenedione and testosterone. All statistical tests were
two-sided, and statistical significance was taken as Po0.05. All
analyses were performed using Stata Statistical Software release 10
(Stata Corp., College Station, TX, USA).
RESULTS
Collaborating studies and participant characteristics
A total of 13 studies contributed data, 7 in the United States of
America, 1 each in Australia, Italy, Japan, Sweden and the United
Kingdom, and the multi-centre European study EPIC (Table 2). In
all, 6291 women contributed data to the analyses. Mean age at
blood sampling ranged from 58.5 years in the Guernsey Study up
to 71.7 years in SOF, with an overall mean of 61.7 years. Body mass
index was available for all except one study (CLUE I), with an
overall mean of 26.4 kg m2. Type of menopause was available for
all except one study (RERF), with most women in the other studies
having had a natural (non-surgical) menopause. Smoking data
were available for all studies and the proportion of current
smokers ranged from 7.2% in SOF to 26.0% in Malmo¨/Umea˚, with
an overall proportion of 13.2%. Alcohol consumption data were
available for eight studies and the proportion of current alcohol
consumers ranged from 37.8% in NYU WHS to 70.0% in WHI-OS,
with an overall proportion of 54.5%.
Correlations between hormones
Concentrations of all the sex hormones were positively correlated
with each other (Table 3); partial correlation coefficients ranged
between 0.29 and 0.93. Free oestradiol was strongly correlated with
total oestradiol (r¼ 0.93) and inversely correlated with SHBG
(r¼0.42). Free testosterone was strongly correlated with total
testosterone (r¼ 0.89) and inversely correlated with SHBG
(r¼0.41). Sex hormone-binding globulin was weakly inversely
correlated with each of the remaining sex hormones, except for
testosterone. Similar correlations between hormones and SHBG
were observed for studies that had used assays with a purification
Table 2 Participant characteristics
Study, country
Number of
womena
Mean age,
years
Age range,
years
Mean BMI,
kgm2
Natural
menopause, %
Current
smokers, %
Alcohol
consumers, %
CLUE I, USA 194 61.4 38–96 NA 100.0 22.4 NA
Columbia, MO, USA 133 61.8 50–76 26.6 72.2 12.8 NA
EPIC, Europeb 1304 60.1 44–76 26.8 82.5 14.7 66.3
Guernsey, UK 177 58.5 45–79 25.6 94.9 18.8 NA
Malmo¨/Umea˚, Sweden 436 60.0 46–73 26.0 96.1 26.0 69.0
MCCS, Australia 1146 60.4 40–70 27.4 79.4 8.5 40.8
Nurses’ Health Study, USA 641 61.4 46–69 26.2 74.8 12.5 58.1
NYU WHS, USA 563 58.9 44–65 25.4 76.7 8.1 37.8
ORDET, Italy 245 58.1 47–69 26.6 78.4 10.2 56.3
Rancho Bernardo, USA 582 66.7 50–79 24.6 72.5 22.6 NA
RERF, Japan 56 59.3 41–77 22.1 NA 16.7 NA
SOF, USA 378 71.7 65–87 26.6 86.2 7.2 41.0
WHI-OS, USA 436 64.5 50–80 27.7 65.1 7.4 70.0
All studies 6291 61.7 38–96 26.4 80.1 13.2 54.5
Abbreviations: BMI, body mass index; CLUE¼Washington County, MD Study ‘Give us a clue to cancer and heart disease’; DHEAS¼ dehydroepiandrosterone sulphate;
EPIC¼ European Prospective Investigation into Cancer and Nutrition; MCCS¼Melbourne Collaborative Cohort Study; NA¼ not available; NYU WHS¼New York University
Women’s Health Study; ORDET¼ Study of Hormones and Diet in the Etiology of Breast Tumors; RERF¼Radiation Effects Research Foundation; SHBG¼ sex hormone-binding
globulin; SOF¼ Study of Osteoporotic Fractures; WHI-OS¼Women’s Health Initiative, Observational Study. aNumber of women with one or more sex hormone
measurements. The numbers of women with measurements of oestradiol, free oestradiol, oestrone, androstenedione, DHEAS, testosterone, free testosterone and SHBG were
5614, 5003, 3848, 5181, 5389, 5666, 5494 and 5678, respectively. bFrance, Germany, Greece, Italy, The Netherlands, Spain and the United Kingdom.
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step for oestradiol, oestrone, androstenedione and testosterone
and for studies that had used direct assays for these hormones
(results not shown).
Age
All the hormones and SHBG were significantly associated with age
but not always in a linear pattern (Figure 1). Concentrations of
oestradiol, oestrone and testosterone were highest in the youngest
age group (below 55 years), after which they declined and did not
vary much thereafter. Androstenedione and DHEAS were 23% and
44% lower, respectively, in women aged 70 years and above than in
women aged below 55 years. Sex hormone-binding globulin was
21% higher in women aged 70 years and above than in women
aged below 55 years. Calculated free oestradiol and calculated free
testosterone were 16% and 18% lower, respectively, in women aged
70 years and above than in women aged below 55 years. There was
significant heterogeneity (Po0.01) between studies in the associa-
tions of oestradiol, oestrone, testosterone, free testosterone and
SHBG with age; for these hormones (but not for SHBG), there was
no significant association with age from studies that had used
assays with a purification step, but there were significant inverse
associations with age from studies that had used direct assays
(results not shown).
Women who had a natural menopause within 5 years of blood
collection had significantly higher circulating concentrations of
oestradiol and free oestradiol than women who had a natural
menopause at least 5 years previously (Table 4). Excluding women
who had undergone menopause o5 years before blood collection,
and women aged below 60 years at blood collection who had an
unknown age at menopause, reduced but did not eliminate the
difference in oestradiol, free oestradiol and oestrone concentra-
tions between women aged o55 and older women, but had little
impact on the associations of age with the other hormones and
SHBG (results not shown).
Type of menopause
Oestradiol, oestrone and SHBG did not differ significantly by type
of menopause (Figure 2). Calculated free oestradiol was 7% lower
in women who had undergone a bilateral ovariectomy than in
women who had a natural menopause. Compared with women
with a natural menopause, concentrations of androstenedione and
DHEAS were 5% and 10% lower, respectively, for women who had
had a hysterectomy and 13% and 11% lower, respectively, for
women who had had a bilateral ovariectomy. Testosterone was
15% lower for women who had had a hysterectomy and 30% lower
for those who had had a bilateral ovariectomy than for women who
had had a natural menopause, with similar differences in
calculated free testosterone. There was significant heterogeneity
between studies in the associations of androstenedione and
testosterone with type of menopause; for androstenedione, the
association with type of menopause was not significant for studies
that had used a purification step but was significant for those that
had used direct assays, whereas for testosterone the association
with type of menopause was significant regardless of whether the
assays had used a purification step (results not shown).
Body mass index
All the hormones and SHBG were significantly associated with BMI
(Figure 3). Oestrogen concentrations were much higher in obese
(BMI at least 30 kg m2) than in thin women (BMIo22.5 kg m2):
oestradiol by 47%, calculated free oestradiol by 89% and oestrone
by 47%. Concentrations of three androgens were also higher in
obese than in thin women: androstenedione by 16%, testosterone
by 17% and calculated free testosterone by 72%, whereas DHEAS
showed significant heterogeneity by BMI but no clear trend. Sex
hormone-binding globulin was 46% lower in obese women than in
thin women. The associations of oestrogens, androgens and SHBG
with BMI were similar in the subgroup of women who had
undergone a bilateral ovariectomy (results not shown). There was
significant heterogeneity between studies in the associations of
oestradiol, free oestradiol and SHBG with BMI; for oestradiol and
free oestradiol, the difference between extreme categories of BMI
was significant regardless of the type of assay, but was larger in the
studies that had used a purification step than in the studies that
had used direct assays (increases from the lowest to the highest
BMI category of 82% and 30%, respectively, for oestradiol and
129% and 70%, respectively, for free oestradiol; results not shown).
Smoking
Concentrations of all the sex hormones were higher for women
who smoked 15þ cigarettes per day than for never smokers
(Figure 4). The largest differences were for androstenedione,
testosterone and calculated free testosterone, which were 18%, 20%
and 19%, respectively, higher for heavy cigarette smokers than for
never smokers. Sex hormone-binding globulin did not differ
according to smoking status. There was no significant hetero-
geneity between studies in the associations of smoking with the
hormones or SHBG. The associations of hormones with smoking
were less marked before adjustment for BMI, but were almost
unaltered after further adjustment for alcohol (results not shown).
Alcohol
Concentrations of all the sex hormones were higher for women
who consumed 20þ g per day of alcohol than for non-drinkers
(Figure 5). The largest difference was for DHEAS, which was 25%
higher for women consuming 20þ g per day of alcohol than for
non-drinkers. Circulating SHBG was 10% lower for women
consuming 20þ g per day of alcohol than for non-drinkers. There
was no significant heterogeneity between studies in the associations
of alcohol with the hormones or SHBG. The associations of
hormones with alcohol were less marked before adjustment for
Table 3 Correlations between hormones and SHBG
Free oestradiol Oestrone Androstenedione DHEAS Testosterone Free testosterone SHBG
Oestradiol 0.93 0.50 0.29 0.29 0.35 0.35 0.08
Free oestradiol 0.50 0.29 0.31 0.32 0.47 0.42
Oestrone 0.44 0.45 0.41 0.42 0.14
Androstenedione 0.60 0.59 0.56 0.08
DHEAS 0.56 0.56 0.11
Testosterone 0.89 0.02
Free testosterone 0.41
Abbreviations: DHEAS¼ dehydroepiandrosterone sulphate; SHBG¼ sex hormone-binding globulin. Partial correlation coefficients between standardized log-transformed
hormone and SHBG concentrations, adjusted for age at blood collection, type of menopause and body mass index. The number of pairs of observations for each partial
correlation is between 2945 and 5081. All values are statistically significant at Po0.0001, except for the partial correlation between testosterone and SHBG.
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BMI, but were almost unaltered after further adjustment for
smoking (results not shown).
Reproductive and other factors
Oestradiol was 6% lower in women who had menarche at ages 14
years and above than in women who had menarche before 12 years
of age (Table 4). Age at menarche was not associated with the other
hormones or SHBG.
Parity was not associated with any of the hormones or with
SHBG, with the exception of DHEAS, which varied significantly
between categories but with no clear pattern (Table 4). For parous
women, none of the hormones or SHBG varied significantly by age
at first full-term pregnancy.
Time since menopause was associated with oestradiol, calcu-
lated free oestradiol and DHEAS, which were 12%, 17% and 8%
higher, respectively, in women who had had their menopause
within the previous 5 years than in women who had had their
menopause 15 or more years previously (Table 4). The other
hormones and SHBG were not associated with time since
menopause. Examination of time since menopause of 0 –4 years
in finer categories (0–1, 2, 3 and 4) showed that the highest
concentrations of oestradiol were in the category of 0–1 years
since menopause (64.4 pmol l1), with little difference across the
other categories (55.7, 57.2 and 53.7 pmol l1, respectively); a
Hormone and category
Oestradiol (pmol l –1)
Below 55 years
55–59 years
60–64 years
65–69 years
55–59 years
55–59 years
55–59 years
55–59 years
55–59 years
55–59 years
55–59 years
60–64 years
60–64 years
60–64 years
60–64 years
60–64 years
60–64 years
60–64 years
65–69 years
65–69 years
65–69 years
65–69 years
65–69 years
65–69 years
65–69 years
70 years and above
70 years and above
70 years and above
70 years and above
70 years and above
70 years and above
70 years and above
70 years and above
*Means are scaled to the overall geometric mean concentration.
+Values are depicted as a proportion of the mean in the first subset (dotted line). 
#Significant interaction with study (P<0.01).
Testosterone (nmol l –1)
Calculated free testosterone (pmol l –1)
SHBG (nmol l –1)
754 39.4 (37.8–41.0)
11.5 (10.7–12.5)535
1188
1569
1478
724
756
1517
1604
1228
561
11.7 (11.2–12.2)
12.1 (11.7–12.6)
12.7 (12.2–13.2)
13.9 (13.1–14.7)
0.84 (0.79–0.90)
0.79 (0.76–0.82)
0.80 (0.77–0.83)
0.83 (0.80–0.86)
0.89 (0.85–0.93)
1399 (1297–1509)
1515 (1453–1580)
1678 (1619–1739)
2046 (1970–2125)
2478 (2351–2612)
2.03 (1.92–2.16)
2.11 (2.03–2.18)
2.30 (2.23–2.37)
2.36 (2.28–2.43)
2.62 (2.50–2.74)
723
496
1147
1515
1350
673
442
798
1111
1030
467
477
1089
1422
1346
632
1233
1546
1446
757 <0.001
(0.001)
<0.001
(<0.001)
0.001#
(0.001)
<0.001
(<0.001)
<0.001
(<0.001)
0.001#
(0.003)
<0.001#
(<0.001)
<0.001#
(<0.001)
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
57.4 (55.2–59.6)
50.0 (48.6–51.5)
50.0 (48.7–51.4)
51.2 (49.7–52.8)
50.9 (48.4–53.5)
669 0.83 (0.79–0.87)
0.74 (0.71–0.76)
0.73 (0.70–0.75)
0.73 (0.71–0.76)
0.71 (0.66–0.76)
115 (110–120)
108 (105–112)
105 (102–108)
103 (99–106)
107 (102–113)
1456
1575
1156
479
40.6 (39.4–41.8)
40.8 (39.7–42.0)
42.4 (41.0–43.7)
46.7 (44.2–49.4)
1530
1612
1226
556
DHEAS (nmol l –1)
Oestrone (pmol l –1)
Androstenedione (nmol l –1)
Calculated free oestradiol (pmol l–1)
Below 55 years
Below 55 years
Below 55 years
Below 55 years
Below 55 years
Below 55 years
Below 55 years
Mean* (95% Cl) P-het (trend) Relative mean+ and 95% Cln
Figure 1 Geometric mean concentration of selected hormones in postmenopausal women by categories of age at blood collection, adjusted for study,
type of menopause and BMI.
Sex hormones and breast cancer risk factors
Endogenous Hormones and Breast Cancer Collaborative Group
713
British Journal of Cancer (2011) 105(5), 709 – 722& 2011 Cancer Research UK
E
p
id
e
m
io
lo
g
y
similar pattern was seen for calculated free oestradiol (means of
0.93, 0.81, 0.83 and 0.80 pmol l1, respectively).
Family history of breast cancer was not associated with any of
the hormones or SHBG (Table 4). Women who had previously
used hormonal contraceptives had 5% higher oestradiol and
calculated free oestradiol and 6% lower androstenedione than
women who had never used hormonal contraceptives. Women
who had previously used hormonal therapy for menopause had 9%
lower oestrone, 6% lower androstenedione and 7% lower
testosterone than women who had not used hormonal therapy
for menopause.
DISCUSSION
The results suggest that circulating concentrations of sex
hormones are associated with several of the well-established or
suspected risk factors for breast cancer. The strongest associations
were with BMI: concentrations of all the hormones were higher in
obese women than in women with a low BMI, with the largest
differences for calculated free oestradiol and free testosterone.
Ovariectomy was associated with low levels of androgens, and
cigarette smoking and alcohol were associated with moderate
increases in all the sex hormones. Age at menarche, parity, age at
first full-term pregnancy and family history of breast cancer were
not strongly related to any of the hormones examined.
The large sample size provides sufficient power to detect
differences in circulating hormone concentrations between cate-
gories as small as 10% for most of the analyses presented. Some of
the observations replicate well-established associations, whereas
others provide novel information of possible relevance to under-
standing the aetiology of breast cancer, as discussed in more detail
below. Many previous publications on this topic are from the
studies participating in this collaboration, and these publications
are cited together with publications from studies not included in
this collaboration. Limitations of this analysis are that the data are
cross-sectional, and therefore cannot be used to attribute causality,
and that some other potentially important factors such as physical
activity and diet were not included in the analyses. Another
potential limitation is that, with the exception of the RERF Study,
the majority of the women in the contributing studies were of
white European ethnic origin.
For some of the analyses, there was significant heterogeneity in
the results from different studies. Inspection of the results from
individual studies did not show large between-study differences in
the variation of hormone levels by categories of risk factors, and
suggested that the heterogeneity was largely due to differences in
the magnitudes of the associations rather than qualitative
Table 4 Relationships of circulating concentrations of sex hormones and SHBG in postmenopausal women with reproductive and other factors. Values
are geometric means and 95% confidence intervals adjusted for study, age at blood collection, type of menopause and body mass index and scaled to the
overall geometric mean concentration
Factor and
subset
Oestradiol
(pmol l1)
Calculated free
oestradiol
(pmol l1)
Oestrone
(pmol l1)
Androstenedione
(nmol l1)
DHEAS
(nmol l1)
Testosterone
(nmol l1)
Calculated free
T (pmol l1)
SHBG
(nmol l1)
Age at menarche (years)
Below 12 53.6 (51.6 – 55.6) 0.77 (0.74 – 0.81) 109 (105 – 114) 2.26 (2.16 – 2.37) 1816 (1722 – 1914) 0.82 (0.78 – 0.86) 12.3 (11.7 – 13.0) 41.5 (40.1 – 43.0)
12 – 13 51.2 (50.2 – 52.3) 0.74 (0.72 – 0.75) 105 (102 – 107) 2.30 (2.24 – 2.36) 1795 (1743 – 1848) 0.82 (0.80 – 0.84) 12.3 (11.9 – 12.7) 41.9 (41.1 – 42.7)
14 and above 50.5 (49.3 – 51.7) 0.74 (0.72 – 0.76) 109 (106 – 112) 2.27 (2.20 – 2.33) 1790 (1733 – 1849) 0.82 (0.80 – 0.84) 12.4 (12.0 – 12.8) 40.8 (39.9 – 41.7)
P for heterogeneity (trend) 0.033 (0.015) 0.114 (0.108) 0.055 (0.664) 0.708 (0.839) 0.903 (0.689) 0.977 (0.986) 0.883 (0.684) 0.195 (0.187)
Number of full-term pregnancies
None 51.8 (49.8 – 53.8) 0.76 (0.72 – 0.79) 110 (105 – 115) 2.27 (2.16 – 2.38) 1702 (1610 – 1798) 0.82 (0.78 – 0.86) 12.5 (11.8 – 13.2) 40.9 (39.4 – 42.4)
One 53.0 (50.8 – 55.3) 0.76 (0.73 – 0.80) 108 (103 – 112) 2.32 (2.21 – 2.44) 1797 (1699 – 1902) 0.84 (0.80 – 0.89) 12.8 (12.1 – 13.5) 40.3 (38.8 – 41.9)
Two 51.6 (50.2 – 53.0) 0.74 (0.72 – 0.77) 107 (104 – 110) 2.32 (2.25 – 2.39) 1864 (1799 – 1932) 0.82 (0.79 – 0.85) 12.3 (11.9 – 12.8) 41.7 (40.7 – 42.7)
Three 50.6 (49.1 – 52.2) 0.74 (0.71 – 0.76) 106 (103 – 110) 2.28 (2.20 – 2.36) 1841 (1766 – 1921) 0.83 (0.80 – 0.86) 12.5 (12.0 – 13.1) 41.4 (40.2 – 42.6)
Four or more 50.4 (48.9 – 52.1) 0.73 (0.70 – 0.75) 104 (100 – 108) 2.22 (2.13 – 2.30) 1704 (1627 – 1784) 0.79 (0.76 – 0.83) 11.8 (11.3 – 12.4) 42.1 (40.8 – 43.4)
P for heterogeneity (trend) 0.361 (0.092) 0.465 (0.083) 0.477 (0.071) 0.490 (0.326) 0.006 (0.956) 0.383 (0.267) 0.221 (0.103) 0.464 (0.143)
Age at first full-term pregnancya (years)
Below 25 51.8 (50.6 – 53.0) 0.75 (0.73 – 0.77) 107 (105 – 110) 2.28 (2.22 – 2.35) 1797 (1740 – 1856) 0.82 (0.80 – 0.85) 12.4 (12.0 – 12.8) 41.2 (40.4 – 42.1)
25 and above 50.8 (49.7 – 52.0) 0.73 (0.72 – 0.75) 106 (104 – 109) 2.28 (2.22 – 2.34) 1794 (1741 – 1849) 0.82 (0.80 – 0.84) 12.3 (11.9 – 12.7) 41.6 (40.8 – 42.4)
P for heterogeneity 0.249 0.262 0.646 0.955 0.937 0.865 0.640 0.535
Years since menopauseb
0 – 4 57.3 (54.6 – 60.0) 0.84 (0.79 – 0.88) 109 (104 – 115) 2.30 (2.17 – 2.43) 1941 (1819 – 2071) 0.82 (0.77 – 0.87) 12.4 (11.7 – 13.3) 40.1 (38.4 – 41.9)
5 – 14 49.5 (48.3 – 50.7) 0.72 (0.70 – 0.74) 105 (102 – 108) 2.26 (2.20 – 2.32) 1750 (1693 – 1810) 0.81 (0.79 – 0.84) 12.3 (11.9 – 12.7) 41.2 (40.3 – 42.2)
15+ 51.1 (49.2 – 53.0) 0.72 (0.69 – 0.75) 108 (104 – 113) 2.31 (2.21 – 2.41) 1790 (1697 – 1888) 0.84 (0.80 – 0.88) 12.4 (11.8 – 13.1) 42.6 (41.1 – 44.2)
P for heterogeneity (trend) o0.001 (0.003) o0.001 (o0.001) 0.216 (0.922) 0.664 (0.844) 0.017 (0.129) 0.612 (0.603) 0.896 (0.945) 0.194 (0.072)
Family history of breast cancer
No 51.1 (49.9 – 52.4) 0.74 (0.72 – 0.76) 107 (104 – 109) 2.29 (2.22 – 2.36) 1805 (1743 – 1870) 0.81 (0.79 – 0.84) 12.2 (11.8 – 12.7) 41.5 (40.6 – 42.3)
Yes 52.1 (49.4 – 54.9) 0.76 (0.71 – 0.81) 107 (102 – 113) 2.25 (2.10 – 2.42) 1745 (1608 – 1894) 0.86 (0.80 – 0.93) 13.0 (11.9 – 14.1) 41.2 (39.2 – 43.3)
P for heterogeneity 0.534 0.366 0.851 0.704 0.459 0.170 0.210 0.826
Previous use of hormonal contraceptives
No 50.6 (49.6 – 51.5) 0.73 (0.71 – 0.74) 106 (104 – 108) 2.33 (2.28 – 2.39) 1796 (1751 – 1843) 0.83 (0.81 – 0.85) 12.4 (12.0 – 12.7) 41.7 (41.0 – 42.4)
Yes 53.0 (51.5 – 54.5) 0.77 (0.75 – 0.80) 109 (106 – 112) 2.18 (2.11 – 2.25) 1795 (1727 – 1865) 0.81 (0.78 – 0.84) 12.3 (11.8 – 12.8) 40.7 (39.7 – 41.8)
P for heterogeneity 0.010 0.002 0.164 0.001 0.972 0.283 0.895 0.129
Previous use of hormone therapyb
No 51.2 (50.3 – 52.1) 0.74 (0.73 – 0.76) 109 (106 – 111) 2.31 (2.25 – 2.36) 1809 (1762 – 1858) 0.83 (0.81 – 0.85) 12.5 (12.1 – 12.8) 41.5 (40.8 – 42.2)
Yes 51.9 (49.9 – 54.0) 0.75 (0.72 – 0.79) 99 (95 – 104) 2.16 (2.04 – 2.28) 1731 (1630 – 1837) 0.77 (0.73 – 0.82) 11.7 (11.0 – 12.4) 41.2 (39.6 – 42.8)
P for heterogeneity 0.542 0.582 0.001 0.027 0.186 0.022 0.050 0.729
Abbreviations: DHEAS¼ dehydroepiandrosterone sulphate; SHBG¼ sex hormone-binding globulin. aParous women only. bNatural postmenopausal women only. P-values relate
to tests of heterogeneity across categories (trend), the latter obtained by scoring the categories 1, 2, 3y as required.
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differences. It is likely that the accuracy of the assays used varied;
therefore, the results should be interpreted simply as an average
across assays for the available data. The results suggested that the
type of sex hormone assay (with or without a purification step)
influenced some of the results. For example, the association of
oestradiol with BMI was stronger in the studies that had used an assay
with previous purification (see below); in general, hormone assays
that include a purification step are both more sensitive and more
specific than direct, non-extraction assays (Stanczyk et al, 2003).
For oestradiol and testosterone, we calculated estimates of the
concentration of the free hormone using the law of mass action
and the concentration of SHBG, and assumed a fixed concentration of
albumin. We chose not to report estimates of non-SHBG-bound
oestradiol and testosterone, which are often described as ‘bioavail-
able’ because these hormones dissociate readily from albumin. It
should be noted that the calculated non-SHBG-bound oestradiol and
testosterone would be perfectly correlated with free oestradiol and
testosterone, respectively, and therefore that the associations reported
for free oestradiol and free testosterone would be identical for the
non-SHBG-bound concentrations of these hormones.
The hormones were all positively correlated with each other,
presumably because they are all part of the same metabolic pathway.
Whereas oestrogen and progesterone production in premenopausal
women is controlled by feedback mechanisms through the anterior
pituitary and the hypothalamus, the control of sex hormone
production in postmenopausal women is not well understood. The
oestrogens are derived from the androgens, which are secreted by the
adrenal glands and by the stromal tissue of the ovaries. Adrenal
androgen production may be stimulated by stress, as ACTH
stimulates the adrenal cortex to synthesise cortisol and, less
specifically, the adrenal androgens (Azziz et al, 1990; McKenna
et al, 1997). Conversion of androgens to oestrogens is catalysed by the
enzyme aromatase, and the major site of aromatase activity in
postmenopausal women is in the adipose tissue (Grodin et al, 1973).
Age
The large decrease in DHEAS and androstenedione, the small
changes in oestrogens and testosterone and the increase in SHBG
with age are broadly consistent with previous reports (Meldrum
et al, 1981; Moore et al, 1987; Verkasalo et al, 2001; Spencer et al,
2007). The smaller decreases in oestrogens than in two of the three
androgens might suggest that the amount of substrate available
only partly determines oestrogen concentrations, and that synth-
esis by aromatisation may become more active in older women
(Misso et al, 2005).
Hormone and category
Oestradiol (pmol l –1)
Calculated free oestradiol (pmol l –1)
Oestrone (pmol l –1)
Androstenedione (nmol l –1)
DHEAS (nmol l –1)
Testosterone (nmol l –1)
Calculated free testosterone (pmol l –1)
SHBG (nmol l –1)
4190
652
327
322
646
4133
327
651
4155
315
640
315
603
3685
301
347
2660
306
375
708
4016 51.4 (50.6–52.2)
52.1 (50.2–54.2)
49.2 (46.6–51.9)
0.74 (0.73–0.76)
0.75 (0.72–0.79)
0.69 (0.64–0.73)
107 (105–109)
108 (102–113)
103 (98–109)
2.32 (2.27–2.36)
2.20 (2.10–2.31)
2.02 (1.89–2.16)
1835 (1794–1876)
1646 (1557–1741)
1639 (1512–1776)
0.86 (0.84–0.87)
0.73 (0.69–0.77)
0.60 (0.56–0.65)
12.9 (12.6–13.1)
11.2 (10.6–11.9)
8.9 (8.2–9.6)
41.4 (40.8–42.1)
40.4 (38.8–42.0)
43.2 (40.9–45.8)
Mean* (95% Cl) P-het Relative mean+ and 95% Cl
0.212
0.044
0.449
<0.001#
<0.001
<0.001#
<0.001
0.156
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
n
616
3710
3937
Natural menopause
Natural menopause
Natural menopause
Natural menopause
Natural menopause
Natural menopause
Natural menopause
Natural menopause
Hysterectomy
Hysterectomy
Hysterectomy
Hysterectomy
Hysterectomy
Hysterectomy
Hysterectomy
Hysterectomy
Bilateral ovariectomy
Bilateral ovariectomy
Bilateral ovariectomy
Bilateral ovariectomy
Bilateral ovariectomy
Bilateral ovariectomy
Bilateral ovariectomy
Bilateral ovariectomy
*Means are scaled to the overall geometric mean concentration.
+Values are depicted as a proportion of the mean in the first subset (dotted line).
#Significant interaction with study (P<0.01).
Figure 2 Geometric mean concentration of selected hormones in postmenopausal women by categories of type of menopause, adjusted for study, age at
blood collection and BMI.
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It is likely that the relatively high concentrations of oestradiol in
women aged below 55 years are associated with the fact that many
of these women have had their menopause within the last 5 years,
and exclusion of women who had recently had their menopause
reduced this association (see further discussion below in relation
to time since menopause).
Hysterectomy and ovariectomy
Previous analyses of data from studies contributing to this
collaboration (Laughlin et al, 2000) and others (Judd et al,
1974a; Vermeulen, 1976; Davison et al, 2005; Cappola et al, 2007;
Fogle et al, 2007; McTiernan et al, 2008) have shown that
postmenopausal women who have had a bilateral ovariectomy
have lower circulating androgen concentrations than postmeno-
pausal women with intact ovaries. Furthermore, clinical studies
have shown that androgen concentrations are higher in blood
samples from the ovarian veins than in the peripheral circulation,
demonstrating that the ovaries secrete androgens (Grodin et al,
1973; Judd et al, 1974b). Our analyses replicated these relation-
ships; women who had undergone a bilateral ovariectomy had
testosterone concentrations about 30% lower than those of
Hormone and category Mean* (95% Cl) P-het (trend) Relative mean+ and 95% Cln
Oestradiol (pmol l –1)
1020
1354
1157
806
1055
945
1250
1066
732
937
758
980
781
495
617
946
1263
1077
731
947
1021
1353
1152
793
1005
1039
1400
1195
827
1045
1036
1389
1189
821
1037
1081
1423
1209
835
1050 30.2 (29.2–31.1)
35.5 (34.3–36.8)
40.1 (39.0–41.3)
46.7 (45.4–47.9)
56.2 (54.5–58.0)
16.5 (15.8–17.3)
13.9 (13.3–14.7)
12.4 (11.9–12.9)
11.0 (10.6–11.5)
9.6 (9.2–10.1)
0.91 (0.87–0.94)
0.84 (0.81–0.88)
0.81 (0.78–0.84)
0.79 (0.76–0.82)
0.78 (0.75–0.81)
1788 (1711–1869)
1840 (1751–1934)
1856 (1782–1934)
1834 (1765–1904)
1658 (1586–1732)
2.49 (2.40–2.58)
2.33 (2.23–2.43)
2.28 (2.20–2.36)
2.22 (2.15–2.29)
2.14 (2.06–2.22)
135 (130–140)
115 (110–119)
108 (105–112)
99 (96–102)
92 (89–95)
1.04 (1.01–1.08)
0.83 (0.80–0.87)
0.74 (0.72–0.77)
0.67 (0.65–0.69)
0.55 (0.53–0.58)
63.9 (61.9–65.9)
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
54.6 (52.6–56.6)
50.1 (48.6–51.6)
48.1 (46.8–49.5)
43.6 (42.2–45.0) <0.001#
(<0.001)
<0.001#
(<0.001)
<0.001
(<0.001)
<0.001
(<0.001)
0.002
(0.049)
<0.001
(<0.001)
<0.001
(<0.001)
<0.001#
(<0.001)
Calculated free oestradiol (pmol l –1)
Oestrone (pmol l –1)
Androstenedione (nmol l –1)
DHEAS (nmol l –1)
Testosterone (nmol l –1)
Calculated free testosterone (pmol l –1)
SHBG (nmol l –1)
<22.5 kg m–2
<22.5 kg m–2
<22.5 kg m–2
<22.5 kg m–2
<22.5 kg m–2
<22.5 kg m–2
<22.5 kg m–2
<22.5 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
22.5–24.9 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
25.0–27.4 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
27.5–29.9 kg m–2
30.0+ kg m–2
30.0+ kg m–2
30.0+ kg m –2
30.0+ kg m–2
30.0+ kg m–2
30.0+ kg m–2
30.0+ kg m–2
30.0+ kg m–2
*Means are scaled to the overall geometric mean concentration.
+Values are depicted as a proportion of the mean in the first subset (dotted line).
#Significant interaction with study (P<0.01).
Figure 3 Geometric mean concentration of selected hormones in postmenopausal women by categories of BMI, adjusted for study, age at blood
collection and type of menopause.
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naturally postmenopausal women, together with smaller reduc-
tions in androstenedione and DHEAS, but no significant
differences for total oestradiol or oestrone. Women who had
undergone a hysterectomy without bilateral ovariectomy had
circulating androgen concentrations intermediate between those of
women who had a natural menopause and women who had
undergone a bilateral ovariectomy; this intermediate effect might
be due to misclassification of some women who had undergone
bilateral ovariectomy into the hysterectomy category and/or
damage to the ovarian blood supply during hysterectomy
(Laughlin et al, 2000); alternatively, it is possible that long-
standing differences in circulating androgens somehow influence
the likelihood of hysterectomy.
Body mass index
Levels of the oestrogens were higher in women with higher BMI,
probably because women with more adipose tissue have more
aromatase (in their adipose tissue) and therefore increased total
aromatase activity (Grodin et al, 1973), and the high oestrogen
levels of obese postmenopausal women probably explain their
increased risk for breast cancer (Endogenous Hormones and
Breast Cancer Collaborative Group, 2003a). This relationship has
been observed in many previous studies that are not included in
this collaboration (Meldrum et al, 1981; Kaye et al, 1991; Madigan
et al, 1998; Nagata et al, 2000; Verkasalo et al, 2001; Boyapati et al,
2004; McTiernan et al, 2006; Chavez-MacGregor et al, 2008).
Androstenedione and testosterone also increased with increasing
BMI, whereas DHEAS was not clearly related to BMI. These
associations have been observed previously (Cappola et al, 2007),
but the reason why androgens increase with BMI is not clear.
Obesity is associated with increases in insulin, which may
stimulate androgen production in the ovarian stroma (Barber
et al, 2006), whereas adrenal androgen synthesis is not known to
be stimulated by insulin; however, our results suggested that
androgens also increased with BMI in women who had undergone
Hormone and category Mean* (95% Cl) P-het
3129
1424
294
352
2876
1244
281
328
1950
1034
282
294
2881
1323
333
353
3103
1357
355
364
3188
1378
356
357
3169
1367
352
356
3251
1392
365
370
41.6 (40.8–42.3)
14.4 (13.3–15.5)
13.0 (12.0–14.0)
12.3 (11.8–12.8)
12.1 (11.8–12.4)
0.97 (0.91–1.04)
0.87 (0.81–0.93)
0.81 (0.78–0.83)
0.81 (0.79–0.82)
2067 (1919–2226)
1869 (1734–2014)
1712 (1647–1778)
1796 (1751–1842)
2.28 (2.23–2.33)
115 (109–121)
107 (101–113)
104 (102–107)
107 (105–109)
0.83 (0.78–0.89)
0.75 (0.70–0.80)
0.74 (0.72–0.77)
0.73 (0.72–0.75)
57.6 (54.5–60.9)
51.8 (48.8–55.0)
51.0 (49.6–52.4)
50.8 (49.8–51.7) <0.001
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.5 0.75 1.0 1.5 2.0
0.002
0.019
<0.001
<0.001
<0.001
<0.001
0.173
2.17 (2.10–2.24)
2.40 (2.25–2.55)
2.68 (2.52–2.85)
40.6 (39.5–41.7)
41.3 (39.2–43.6)
43.4 (41.1–45.8)
Relative mean+ and 95% Cln
Oestradiol (pmol l –1)
Calculated free oestradiol (pmol l –1)
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Current (<15 cigs per day)
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*Means are scaled to the overall geometric mean concentration.
+Values are depicted as a proportion of the mean in the first subset (dotted line).
Figure 4 Geometric mean concentration of selected hormones in postmenopausal women by categories of smoking, adjusted for study, age at blood
collection, type of menopause and BMI.
Sex hormones and breast cancer risk factors
Endogenous Hormones and Breast Cancer Collaborative Group
717
British Journal of Cancer (2011) 105(5), 709 – 722& 2011 Cancer Research UK
E
p
id
e
m
io
lo
g
y
a bilateral ovariectomy and in whom most androgen synthesis
must be in the adrenals. Sex hormone-binding globulin also
decreased with increasing BMI, as has been consistently observed
in many studies (e.g., Baglietto et al, 2009; Moore et al, 1987; and
Newcomb et al, 1995); this decrease may be due to raised insulin
concentrations inhibiting SHBG synthesis in the liver (Crave et al,
1995).
Overall, total oestradiol was 47% higher and calculated free
oestradiol was 89% higher in obese women than in thin women.
There was significant heterogeneity between studies in these
estimates, and some of this heterogeneity was explained by the
oestradiol assay method, with increases of total oestradiol between
thin and obese women of 82% for studies that used assays with
previous purification but only 30% for studies that used direct
non-extraction assays. A similar difference has been noted
previously, and it is likely that the larger estimate of 82% is more
accurate because assays with previous purification for oestradiol
are more sensitive and more specific than direct assays (Lee et al,
2006).
Smoking
We observed higher concentrations of oestrogens and androgens
in current heavy cigarette smokers (at least 15 cigarettes per day)
than in non-smokers, whereas SHBG did not vary significantly
according to smoking status. Cigarette smokers were on average
thinner than non-smokers, and the differences in oestrogens were
accentuated by the adjustment for BMI. Previous studies have not
shown clear associations of smoking with circulating oestrogens,
but have generally observed that at least some of the androgens
were higher in smokers than in non-smokers (Khaw et al, 1988;
Cassidenti et al, 1992; Baron et al, 1995; Manjer et al, 2005). The
Hormone and category
Oestradiol (pmol l –1)
Calculated free oestradiol (pmol l –1)
Oestrone (pmol l –1)
Androstenedione (nmol l –1)
DHEAS (nmol l –1)
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2100
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0.002
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<0.001
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Relative mean+ and 95% Cl
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2.42 (2.29–2.56)
2.21 (2.14–2.29)
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0.76 (0.73–0.80)
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56.2 (53.6–58.9)
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*Means are scaled to the overall geometric mean concentration.
+Values are depicted as a proportion of the mean in the first subset (dotted line).
Figure 5 Geometric mean concentration of selected hormones in postmenopausal women by categories of usual alcohol consumption, adjusted for
study, age at blood collection, type of menopause and BMI.
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mechanism for these associations is unknown but may involve
more general effects on the hypothalamic –pituitary – adrenal axis
(Kapoor and Jones, 2005).
Most epidemiological studies have suggested that smoking has
little or no effect on breast cancer risk (Collaborative Group on
Hormonal Factors in Breast Cancer, 2002; International Agency for
Research on Cancer, 2004), but some recent large cohort studies
have suggested that a long duration of smoking does have a small
positive association with breast cancer risk in postmenopausal
women, particularly in association with starting to smoke at a
young age (Cui et al, 2006; Luo et al, 2011) and perhaps because of
the chemical carcinogens in tobacco smoke (Secretan et al, 2009).
The moderate differences between heavy smokers and non-
smokers in circulating hormones might affect breast cancer risk,
although the total effect of smoking on lifetime exposure to
hormones also includes the relatively early menopause of smokers
(Midgette and Baron, 1990) and possibly changes in oestrogen
metabolism (Michnovicz et al, 1986).
Alcohol
Alcohol intake was positively associated with all the sex hormones,
with the strongest association for DHEAS, whereas SHBG was
inversely associated with alcohol consumption.
High alcohol consumers were on average thinner than non-
drinkers, and the differences in oestrogens and in SHBG were
accentuated by the adjustment for BMI. These findings are broadly
consistent with those of previous observational studies (Onland-
Moret et al, 2005). Furthermore, a randomised trial in 51
postmenopausal women showed that DHEAS increased by 5.1%
in women consuming 15 g of alcohol per day and by 7.5% in
women consuming 30 g of alcohol per day; alcohol consumption
also increased circulating concentrations of oestrone sulphate
(Dorgan et al, 2001). In another randomised crossover trial in nine
postmenopausal women, 30 g of alcohol per day increased
circulating DHEAS by 18% but had no detectable effect on
oestradiol or testosterone (Sierksma et al, 2004). The mechanism
for these associations is unknown.
Alcohol is mostly consumed in the evening, whereas blood
samples are usually collected during the day. As the half-life of
oestradiol isB3 h (Ginsburg et al, 1998), it is possible that there is
a marked increase of oestradiol shortly after alcohol consumption
in the evening, which cannot be assessed in typical epidemiological
studies. In a study of the acute effects of 40 g of alcohol in
premenopausal women, circulating oestradiol concentrations
increased and reached a peak 25 min after alcohol ingestion
(Mendelson et al, 1988). The half-life of DHEAS is longer (B14 h),
and this might explain why this sulphated hormone has the
strongest association with alcohol consumption (Dorgan et al,
2001).
The increases in sex hormone concentrations associated with
alcohol consumption might contribute to the increase in breast
cancer risk with alcohol consumption (Baan et al, 2007), although
other factors not related to circulating hormone concentrations
might mediate the effect (Seitz and Stickel, 2007).
Other risk factors
Early research suggested that young age at menarche is positively
associated with oestrogen levels in young women (MacMahon
et al, 1982), but previous studies have not demonstrated clear
associations of age at menarche with circulating hormones in
postmenopausal women (Verkasalo et al, 2001). We found that,
after adjusting for BMI, mean concentrations of oestradiol were 6%
lower in postmenopausal women who had had a late menarche
than in those who had an early menarche, but age at menarche was
not clearly associated with the other hormones or SHBG.
The mean concentration of DHEAS varied significantly with
parity, but without a clear pattern. Previous studies have reported
that parity was not associated with sex hormones in postmeno-
pausal women (Ness et al, 2000) and that DHEAS was not
significantly related to parity in postmenopausal women (Key et al,
1990). Age at first full-term pregnancy in parous women was not
associated with any of the sex hormones or SHBG.
Age at menarche, parity and age at first full-term pregnancy
are risk factors for breast cancer (Kelsey et al, 1993). Apart from
the very weak association of age at menarche with circulating
oestradiol, the current findings that these risk factors are not
associated with circulating sex hormone concentrations in
postmenopausal women suggest that their effects on breast
cancer risk are not likely to be mediated through postmenopausal
hormone levels. These risk factors may operate through long-term
effects on sex hormone levels in premenopausal women (MacMahon
et al, 1982), through changes in the duration rather than
the level of exposure to premenopausal sex hormones (Key and
Pike, 1988), by hormonally mediated long-lasting changes in breast
structure (Russo et al, 2005) or by other mechanisms.
Mean concentrations of oestradiol, free oestradiol and
DHEAS were significantly higher in women who had had their
menopause within 5 years of blood collection than in other
women, but the other sex hormones and SHBG did not differ
significantly between these groups. The higher levels of oestradiol
and free oestradiol were observed primarily up to about 1 year
after menopause, and this is compatible with results from a
longitudinal study in which oestradiol levels declined from about
2 years before the final menstrual period until B2 years after
(Sowers et al, 2008). In another report from the same longitudinal
study (Crawford et al, 2009), there was a small increase in
circulating concentrations of DHEAS during the menopausal
transition, followed by a decline (more than 2 years since last
menstrual period).
Previous use of exogenous sex hormones was significantly
associated with several endogenous hormones, although the magni-
tude of these associations was small. Previous use of oral contra-
ceptives was associated with higher concentrations of oestradiol and
free oestradiol and lower concentrations of androstenedione; previous
use of hormonal therapy for menopause was associated with lower
concentrations of oestrone, androstenedione, testosterone and free
testosterone. In another study (Chan et al, 2008), previous use of oral
contraceptives was associated with lower concentrations of oestradiol,
oestrone, androstenedione, testosterone and SHBG, and previous use
of hormonal therapy for the menopause was associated with lower
concentrations of testosterone and 17a-hydroxyprogesterone. It is
possible that the associations with hormonal therapy for menopause
may be partly because women with relatively low endogenous
hormone levels may have more symptoms, and therefore be more
likely to be prescribed hormonal therapy.
CONCLUSIONS
Circulating sex hormone concentrations in postmenopausal
women are strongly associated with several established or
suspected risk factors for breast cancer, and may mediate the
effects of these factors on breast cancer risk.
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